CAD Clinical Trials
NORD and other rare disease organizations around the world will celebrate Rare Disease Day on February 28, 2022, with most events being held virtually.
Abstract artist Betty Usdan-Zwickler, 83, of Boca Raton, Florida, is also a fierce advocate for fellow patients with cold agglutinin disease (CAD).
The all-volunteer CAD Foundation fights for patients with a rare anemia that has no approved therapy. Three companies are conducting clinical trials.
Given the rarity of CAD and lack of comparative trials, treatment plans are primarily based on findings from nonrandomized trials and clinical experience.
Obviously, dehydration is dangerous for anyone, especially if it is extreme. However, for people with conditions like CAD, it has an added level of urgency.
CAD is not a well-known disease, which means it is typically up to the patient to instruct the physician on the steps necessary to be safe.
The year prior to my diagnosis, I had daily stomach issues and dark urine. I did not know it at the time, but I was experiencing hemolysis.
Because cold agglutinin disease (CAD) is a rare subset of another rare disease, very few medical researchers devote entire studies to exploring it.
We examine the lasting impact of innovative clinical trial designs for rare diseases on other clinical experiments.
Cold agglutinin disease, like seasonal affective disorder and Raynaud’s phenomenon, can be adversely affected by the climate.
Infections are often overlooked in autoimmune hemolytic anemia (AIHA), although they can impact morbidity and mortality of patients.
Autoimmune hemolytic anemia, of which cold agglutinin disease is a subtype, is one of several autoimmune diseases that involve an aberrant inflammatory pathway.
We discuss the sharp rise of telemedicine services in the US and what it means for cystic fibrosis patient care.
Rare Care Podcast